481 related articles for article (PubMed ID: 30917829)
1. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
[TBL] [Abstract][Full Text] [Related]
2. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
[TBL] [Abstract][Full Text] [Related]
3. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.
Ehrig K; Kilinc MO; Chen NG; Stritzker J; Buckel L; Zhang Q; Szalay AA
J Transl Med; 2013 Mar; 11():79. PubMed ID: 23531320
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
8. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
[TBL] [Abstract][Full Text] [Related]
9. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
11. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
12. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Evgin L; Acuna SA; Tanese de Souza C; Marguerie M; Lemay CG; Ilkow CS; Findlay CS; Falls T; Parato KA; Hanwell D; Goldstein A; Lopez R; Lafrance S; Breitbach CJ; Kirn D; Atkins H; Auer RC; Thurman JM; Stahl GL; Lambris JD; Bell JC; McCart JA
Mol Ther; 2015 Jun; 23(6):1066-1076. PubMed ID: 25807289
[TBL] [Abstract][Full Text] [Related]
13. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.
Morales-Molina Á; Gambera S; Cejalvo T; Moreno R; Rodríguez-Milla MÁ; Perisé-Barrios AJ; García-Castro J
Cancer Immunol Immunother; 2018 Oct; 67(10):1589-1602. PubMed ID: 30066102
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic viruses for induction of anti-tumor immunity.
Tong AW; Senzer N; Cerullo V; Templeton NS; Hemminki A; Nemunaitis J
Curr Pharm Biotechnol; 2012 Jul; 13(9):1750-60. PubMed ID: 21740355
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic cancer therapy with a vaccinia virus strain.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B; Hu Z
Oncol Rep; 2019 Jan; 41(1):686-692. PubMed ID: 30365140
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
[TBL] [Abstract][Full Text] [Related]
18. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J
Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725
[TBL] [Abstract][Full Text] [Related]
19. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E; Malorzo C; Capasso C; Honkasalo O; Fusciello M; Martins B; Ylösmäki L; Louna A; Feola S; Paavilainen H; Peltonen K; Hukkanen V; Viitala T; Cerullo V
Mol Ther; 2018 Sep; 26(9):2315-2325. PubMed ID: 30005865
[TBL] [Abstract][Full Text] [Related]
20. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.
Weibel S; Raab V; Yu YA; Worschech A; Wang E; Marincola FM; Szalay AA
BMC Cancer; 2011 Feb; 11():68. PubMed ID: 21320309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]